



**Supplementary Figure S4.** Frequency of recurrent somatic alterations compared to published cohorts. Only ctDNA positive samples from the OPTIMUM and ILUMINATE were used for frequency assessment. The frequencies were compared to primary prostate cancer from The Cancer Genome Atlas (TCGA) [6], metastatic castration-sensitive prostate cancer (mCSPC) from Stopsack et al. 2020 [7] and metastatic castration-resistant prostate cancer (mCRPC) from Abida et al. 2019 [8]. Note that different sequencing platforms, materials and bioinformatic analysis were used in the different study populations, hampering direct comparison.